Lyme Disease Diagnostics Market to Reach Over US$ 2.1 Billion by 2031, Driven by Rising Disease Incidence and Advancements in Diagnostic Technologies | Latest Report TMR

The global Lyme disease diagnostics market was valued at US$ 1.5 Billion in 2022 and is projected to surpass US$ 2.1 Billion by 2031, expanding at a compound annual growth rate (CAGR) of 3.8% from 2023 to 2031. The market is witnessing steady growth due to increasing disease prevalence and growing awareness regarding early diagnosis and treatment.

Access key findings and insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1658

Market Overview

Lyme disease diagnostics represents a crucial segment within the global healthcare diagnostics industry. Lyme disease, caused by the bacterium Borrelia burgdorferi, is a tick-borne illness transmitted to humans through infected blacklegged ticks. Common symptoms include fever, fatigue, headache, and characteristic skin rash, which may lead to severe complications if not treated in time.

The rising prevalence of Lyme disease, particularly in regions with high tick populations, has significantly increased the demand for accurate and timely diagnostic solutions. As early detection is critical for effective treatment, healthcare providers are increasingly relying on advanced diagnostic technologies.

The market has evolved with the introduction of innovative testing methodologies such as nucleic acid amplification tests (NAATs), enzyme immunoassays (EIAs), and multiplex assays. These technologies offer improved sensitivity, specificity, and faster turnaround times, making them essential tools in modern diagnostic practices.

Key Market Growth Drivers

Rise in Incidence of Lyme Disease

The increasing number of Lyme disease cases globally is a primary driver of market growth. According to the CDC, confirmed Lyme disease cases in the U.S. increased significantly between 1999 and 2019. Furthermore, research published in BMJ Global Health in June 2022 indicates that over 14% of the global population shows evidence of Lyme disease exposure through antibodies.

Higher disease prevalence, particularly in North America and Europe, has led to increased awareness and demand for diagnostic testing. Continuous mutations and genetic variations in the causative bacteria further contribute to the complexity of diagnosis, necessitating advanced testing solutions.

Growth in Awareness and Diagnostic Advancements

Growing awareness among healthcare professionals and the general population regarding the importance of early diagnosis is boosting market demand. In parallel, advancements in diagnostic technologies are enhancing the accuracy and efficiency of testing.

Technologies such as ELISA, western blot, and molecular diagnostic tools have become standard practices in identifying Lyme disease. Increased funding from governments and private organizations for research and development is also accelerating innovation, creating new opportunities for diagnostic providers.

Analysis of Key Players
The global Lyme disease diagnostics market is fragmented, with several key players contributing to technological advancements and competitive dynamics. Major companies include LabCorp, Quest Diagnostics, Abbott Laboratories, Bio-Rad Laboratories, Inc., bioMérieux SA, DiaSorin S.p.A, T2 Biosystems, Inc., F. Hoffmann-La Roche AG, Meridian Bioscience, Inc., Quidel Corporation, and Thermo Fisher Scientific Inc.

These companies are actively engaged in strategic initiatives such as mergers and acquisitions, partnerships, collaborations, and new product launches to strengthen their market presence. Their focus on innovation and adoption of advanced diagnostic technologies enables them to cater to evolving healthcare demands and maintain a competitive edge.

Market Challenges & Opportunities

The Lyme disease diagnostics market faces challenges such as limited availability of highly accurate diagnostic tests and the complexity associated with detecting different bacterial strains due to genetic variability. Additionally, misdiagnosis and delayed detection remain concerns in certain regions with limited healthcare infrastructure.

However, these challenges present significant growth opportunities. Continuous advancements in molecular diagnostics, increased funding for research, and expanding healthcare infrastructure in emerging markets are expected to drive innovation. The development of highly sensitive and specific diagnostic tools, along with improved accessibility to testing services, is likely to create lucrative opportunities for market players.

Recent Developments

• In April 2023, Abbott Laboratories announced a collaboration with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, a group of more than 100 scientists from public health departments and other industries. These global scientists are striving to assess and potentially mitigate the impact of climate change on disease outbreaks using data science technology and diagnostic testing.

• In July 2022, T2 Biosystems, Inc. announced that the FDA granted Breakthrough Device Designation for the company's T2Lyme Panel. The T2Lyme Panel is a direct-from-blood molecular diagnostic test introduced to detect the Lyme disease-causing bacteria, including Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii. The test runs on the FDA-cleared T2Dx Instrument.

• In June 2022, Quidel Corporation announced a multifaceted partnership with Global Lyme Alliance in an effort to significantly raise public awareness about Lyme disease, which affects nearly 500,000 people in the U.S. annually. The first rapid point-of-care diagnostic Lyme disease test with FDA approval was developed by Quidel Corporation.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/lyme-disease-diagnostic.html

Market Segmentation

By Test Type

• Serological Tests (ELISA, Western Blot)
• Molecular Diagnostic Tests (NAATs)
• Others

The serological test segment dominates the market due to its affordability, high sensitivity, and widespread availability. ELISA remains the most commonly used test, offering reliable detection of antibodies against the Lyme disease-causing bacteria.

By Sample Type
• Blood Samples (Dominant segment)
• Others

Blood samples are the most widely used for Lyme disease diagnosis due to ease of collection and compatibility with multiple testing methodologies.

By End-user
• Diagnostic Laboratories (Leading segment)
• Hospitals
• Others

Diagnostic laboratories lead the market owing to cost efficiency, faster turnaround times, and adherence to strict quality standards.

Regional Outlook

North America is expected to dominate the global Lyme disease diagnostics market during the forecast period. The region's leadership is attributed to the high prevalence of Lyme disease, especially in the United States, along with a well-established healthcare infrastructure and availability of advanced diagnostic technologies.

Increasing awareness among healthcare professionals and the general population is encouraging early testing and diagnosis. Additionally, strong research and development activities and technological advancements are further driving market growth in North America.

Europe also represents a significant market due to high disease prevalence and strong healthcare systems. Meanwhile, the Asia Pacific region is anticipated to witness steady growth, supported by improving healthcare infrastructure, rising awareness, increasing R&D activities, and government initiatives promoting disease screening programs.

Why Buy This Report?

• Comprehensive analysis of market size, growth trends, and forecasts through 2031
• Detailed insights into key drivers, challenges, and emerging opportunities
• In-depth competitive landscape and company profiling
• Segment-wise and region-wise market intelligence
• Strategic insights to support business planning and investment decisions

Buy this Premium Research Report for exclusive, in-depth insights - https://www.transparencymarketresearch.com/checkout.php?rep_id=1658<ype=S

FAQs

1. What is the current size of the Lyme disease diagnostics market?
The market was valued at US$ 1.5 Billion in 2022.

2. What is the projected market value by 2031?
The market is expected to exceed US$ 2.1 Billion by 2031.

3. What is driving the growth of this market?
Key drivers include rising incidence of Lyme disease, increasing awareness, and advancements in diagnostic technologies.

4. Which segment dominates the market?
Serological tests, particularly ELISA, dominate due to affordability and widespread use.

5. Which region holds the largest market share?
North America leads the market due to high disease prevalence and advanced healthcare infrastructure.

More Trending Reports by Transparency Market Research -

Sleep Apnea Devices Market: https://www.transparencymarketresearch.com/sleep-apnea-devices-market.html

Skin Antiseptic Market: https://www.transparencymarketresearch.com/skin-antiseptic-market.html

Cancer Biomarkers Market: https://www.transparencymarketresearch.com/cancer-biomarkers-market.html

Medical Devices Outsourcing Market: https://www.transparencymarketresearch.com/medical-devices-outsourcing-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.